21 CFR 211.84(d)(2)
Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.84(d)(2): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR 211.84(d)(2)?
- 3 DSRV articles cite 21 CFR 211.84(d)(2). Enforcement cases behind them: FDA Warning Letter 320-26-126 (MARCS-CMS 732028) to Bentley Laboratories LLC, 111 Fieldcrest Avenue, Edison, NJ (FEI 2244819); inspected 03/16-03/27/2026, issued 09/17/2026, posted 09/29/2026; Five coordinated FDA warning letters issued June 2, 2026, including WL 320-26-89 to Revlon Group Holdings (US), WL 320-26-90 to Shantou Qiwei Industry (China), WL 320-26-92 to Umendra Life Sciences and Zydus Lifesciences (India), and WL 320-26-87 to Laboratorios Dr. Collado (Dominican Republic), all citing 21 CFR 211.84(d); FDA Warning Letter 320-26-54, CMS Case 722736, to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026. Inspection exposure across them: 3 high.
- What does DSRV recommend for 21 CFR 211.84(d)(2)?
- From the newest article (Bentley Widened the pH Limit Instead of Finding the Cause): A CAPA that changes the limit and leaves the cause alone closes the record and keeps the risk. The file an inspector wants shows what caused the result, which other lots it reaches, and a limit change justified by data dated independently of the failure. DSRV is decision support, not legal advice; verify against the official source each article names.
- 6 min readHigh exposurecited as a tag
Bentley Widened the pH Limit Instead of Finding the Cause
FDA's warning letter to Bentley Laboratories says an out-of-specification pH result at 36 months was answered with a wider specification range and no scientific justification. The same letter shows what an OOS investigation has to contain.
- Case
- FDA Warning Letter 320-26-126 (MARCS-CMS 732028) to Bentley Laboratories LLC, 111 Fieldcrest Avenue, Edison, NJ (FEI 2244819); inspected 03/16-03/27/2026, issued 09/17/2026, posted 09/29/2026
- DSRV take
- A CAPA that changes the limit and leaves the cause alone closes the record and keeps the risk. The file an inspector wants shows what caused the result, which other lots it reaches, and a limit change justified by data dated independently of the failure.
- 7 min readHigh exposurecited as a tag
FDA Found Zero Asbestos Testing at Five OTC Manufacturers
On June 2, 2026, FDA issued five coordinated warning letters to OTC drug manufacturers across four countries for the same CGMP failure, without a single on-site inspection. The violation is straightforward. What the enforcement mechanism reveals is not.
- Case
- Five coordinated FDA warning letters issued June 2, 2026, including WL 320-26-89 to Revlon Group Holdings (US), WL 320-26-90 to Shantou Qiwei Industry (China), WL 320-26-92 to Umendra Life Sciences and Zydus Lifesciences (India), and WL 320-26-87 to Laboratorios Dr. Collado (Dominican Republic), all citing 21 CFR 211.84(d).
- DSRV take
- Inspection readiness now includes records readiness: what the component testing file shows on any given day is the compliance evidence FDA can request without warning, without a site visit, and without regard to the last inspection outcome.
- 6 min readHigh exposure
The Certificate of Analysis Is Not a Test
FDA's March 2026 warning letter to Yangzhou H&R Plastic documented three co-occurring failures that define small OTC manufacturer inspection risk: batch release without identity testing, a quality unit with no structural independence, and zero process validation before commercial distribution.
- Case
- FDA Warning Letter 320-26-54, CMS Case 722736, to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026.
- DSRV take
- The diagnostic question is not whether incoming materials are tested but whether the person signing incoming material releases has any organizational reason to approve them regardless of the data; if the QU Director also controls the budget that pays suppliers, the org chart is already a finding.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR 211.84(d)(2). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.